International Progressive MS Alliance e-News - March 2021 In this issue: • Read about the recent call to action to prioritise research on symptoms that matter most to people affected…read more
Mavenclad (cladribine) reduces the number and volume of lesions in patients at risk of multiple sclerosis (MS) after a first clinical demyelinating event, a study based on Phase 3 trial…read more
Special issue of Neurology Research Review, focusing specifically on MS.read more
Funded by the International Progressive MS Alliance, a first-of-its-kind global research network aims to develop new, effective treatments for progressive MS.read more
This article, written by the Journal of Multiple Sclerosis and related disorders, (MSARD) includes data from clinical trials, post marketing safety surveillance and a US electronic medical records database, Optum.read more
Pharmac have released public consultation on a proposal to widen access to funded multiple sclerosis treatments and transition access from the Multiple Sclerosis Treatment Assessment Committee (MSTAC) Panel to a…read more
New data on the long term benefits of Ocrelizumab for PPMS has recently been published 29 October 2020 on the Lancet Ocrelizumab is currently funded for RRMS in New Zealand…read more
Note: This article was originally published on www.multiplesclerosisnewstoday.com, written by Marta Figueiredo and fact checked by Patrícia Silva, PHD. MD1003, MedDay Pharmaceuticals’ high-dose biotin therapy, failed to significantly improve functional…read more
Exploring patterns of medicinal cannabis use prior to implementation of the new Medicinal Cannabis Scheme (MCS) in New Zealand.read more
What do the MS treatments ocrelizumab, alemetuzumab and natalizumab (Ocrevus, Lemtrada, and Tysabri) have in common?read more
Study results published show a noticeably reduced risk for progression of upper extremity (UE) disability compared with placebo in patients with primary progressive multiple sclerosis (PPMS)read more
Interferon-Beta, Glatiramer Acetate Equally Effective for Relapsing-Remitting MSread more
There is a great deal of scientific and community interest in the role that stem cells might play in treating MS. Stem cell therapy is a treatment that uses or targets stem…read more
While there has been great progress in the development of effective treatments for relapsing remitting MS over the last 15 years, there has not been the same advances in treatments…read more
Cladribine, an oral treatment for relapsing remitting MS, previously approved in Australia, but subsequently withdrawn, is making a comeback.read more
MS Research Australia has been reporting on every step that Ocrevus a new MS medication, has taken on its journey to become the first ever approved treatment for progressive MS…read more
Our blood brain barrier is an amazing part of the body that keeps the brain and spinal cord highly protected, allowing through only those cells and nutrients that are needed…read more
Canadian researchers have published their results of a clinical trial testing whether an antibiotic commonly used in the treatment of acne can help prevent a diagnosis of MS in people…read more
The American Food and Drug Administration (FDA) has approved OCREVUS™ (ocrelizumab) for the treatment of both relapsing and primary progressive forms of multiple sclerosis.read more
On the ABC News 7-30 Report recently, the MS Research Australia Chief Executive Officer, Dr Matthew Miles, featured in a report discussing the approach to the management of MS founded…read more
